Medical Oncology

Lymphoma   

Questions discussed in this category



TROG 99.03 showed nearly 20% improved PFS at 10 years with chemoimmunotherapy despite 31/75 patients assigned R-CVP vs 44/75 assigned CVP without ritu...

Is there a preference for obinutuzumab over rituximab in early relapsed DLBCL, or in primary refractory disease?

What if the patient has a history of confirmed COVID-19 but has since recovered?

At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...

There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.

There are multiple regimens including IGEV and most recently reported results of BEGEV without preference on NCCN guidelines.

Given the rarity of DLBCL with MYC/BCL2/BCL6 rearrangements, do you approach this disease differently than DLBCL with MYC/BCL2 or BCL6 rearrangement, ...

What features are used to distinguish anaplastic multiple myeloma (AMM), and what other conditions should be considered in a differential diagnosis (e...

Do the potential late effects offset any benefit of mediastinal XRT in a young patient with bulky disease?

Would your choice be affected by which high risk features the patient has (eg. double- or triple-hit status vs IPI score of 3-4)?

There are multiple options that carry a category 2B recommendation in the NCCN guidelines. Does germinal B center type vs activated B-cell type play a...

Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be r...

Specifically, do you consider repeating maintenance therapy after second line therapy if a patient had already received 2 years of maintenance rituxim...

If a young and otherwise healthy patient with normal echocardiogram and no other cardiac risk factors needs treatment for DLBCL, but has previously re...

Specifically, do you utilize 3 cycles of chemo with ISRT or 6 cycles? Do you use R-EPOCH or R-CHOP in these cases?

e.g. mixed indolent/aggressive NHL, mixed NHL/HL? Is there a definitive way to discern composite from transformation? NCCN does not list recommendatio...

How would you handle high risk features (eg double hit) with the limitations of dialysis?

Would you give 3 cycles of RCHOP followed by consolidative IFRT or 6 cycles of R-mini CHOP? Is there a role for 3 cycles of R-mini CHOP followed by IF...

Given nationwide shortage in Vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...

Some specific questions: Would you recommend repeat biopsy to confirm residual disease? How would your recommendations vary if the patient had pre...

I.e., Can day 2 Rituximab (RCHOP) or day 6 Rituximab (DA-EPOCH, Hyper CVAD) be given? Or should only Day 1 Rituximab be used with chemoimmunotherapy i...

Since some prior studies (eg. Eskelund et al. Blood 2017 130:1903-10.) have shown intensive chemoimmunotherapy does not overcome the ad...

Since ECHELON-1 trial showed an improvement in PFS (but not OS), are there any situations where you would replace bleomycin with brentuximab...

Would you follow an algorithm such as the one proposed by Hall et al? How do you decide between intrathecal chemotherapy vs systemic therapy with HD-...

Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?

Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Ritux...

Would you treat differently for de novo disease vs disease arising from large cell transformation of an indolent NHL?

Does their candidacy for autologous HSCT affect your decision to use maintenance lenalidomide?

Does the more recent data regarding the continued utility of brentuximab vedotin and the utility of PD-1 inhibitors factor in to your reasoning at all...

Does it differ from the treatment of other relapsed peripheral T-cell lymphomas? Are there any clinical trials or case series focused on SPTCL? Is t...

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...

Assuming that the involved area is too widespread for RT. Would you try single agent rituximab first? Or obinutuzumab? What if rituximab alone gave on...

The recent NEJM phase II trial http://www.nejm.org/doi/full/10.1056/NEJMoa1715519?query=featured_home looked at a small cohort of 24 patients and show...

the MZL was untreated in the past prior to transformation. Do these patients have a higher risk of recurrence post CR as opposed to patients with de ...

If filgrastim, how many days would you give? Pegfilgrastim is often not covered by payers if given less than 14 days before chemotherapy.  

If the patient cannot tolerate methotrexate or further chemotherapy, how effective is radiation therapy (e.g. WBRT) in rendering the patient disease-f...

Specifically I am thinking if a PET scan shows complete response, would it be reasonable to stop bleomycin and continue AVD?

My experience has been that patients can be neurologically devastated years out from WBRT. In Medical Oncology practice at my institution, we do not r...

PET/CT/bone marrow biopsy negative for evidence of distant disease. Following 4 cycles of combination chemotherapy with no evidence of progressive dis...

Although bendamustine + rituximab is a standard option for advanced follicular lymphoma when treatment is required, does the regimen rituximab + lenal...

How does age play a role in this decision?  If you do intensify therapy, how do you explain the negative results of CALGB/Alliance 50303?

If so, do you use antivirals and/or antibiotics? Does it matter if the patient has mantle cell lymphoma, CLL, or Waldenstrom's macroglobulinemia?

Specifically, is there still a role for dd RCHOP followed by ICE, or do you recommend DA-R-EPOCH for all patients?

NCCN guidelines suggest XRT as standard of care for this stage of disease. However, occasionally patients have their tumors completely excised when un...

If a patient with stage I, low grade follicular lymphoma achieves a complete response after rituxan and treanda is there any role for consolidative ra...


Papers discussed in this category


J. Clin. Oncol., 2014-04-10

J. Clin. Oncol., 2013-11-10

Oncology (Williston Park, N.Y.), 2012-12

N. Engl. J. Med., 2010-08-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-10

J Clin Oncol, 2010 Oct 10

J. Natl. Cancer Inst., 2011 Oct 21

The Lancet. Oncology, 2016-08

J. Clin. Oncol., 2010 May 03

Blood, 2016-10-13

The Lancet. Oncology, 2014-11

The New England journal of medicine, 2016-06-23

Blood, 2013-12-19

Cancer, 2004-05-15

N. Engl. J. Med., 2018-01-25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-15

Lancet, 2009 Sep 18

The New England journal of medicine, 2017-12-28

Avicenna J Med, 2017 Jul-Sep

J. Clin. Oncol.,

Lancet (London, England), 2018-02-17

British journal of haematology, 2017-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-10

J. Clin. Oncol., 2018 Jul 05

Lancet (London, England), 2019-01-19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

J. Clin. Oncol., 2009 Oct 05

Ann. Oncol.,

Cancer Res., 2010 Feb 02

Dig Liver Dis, 2013 Jun 28

Blood, 2018 Sep 04

Blood, 2017-02-02

The Lancet. Haematology, 2016-05

The Lancet. Haematology, 2017-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20

Blood, 2018-03-15

Neuro-oncology, 2009-04

Lancet Haematol, 2015 Jun 03

Radiother Oncol, 2011 Jun 12

Annals of oncology : official journal of the European Society for Medical Oncology, 2011-02

Haematologica, 2016 Jun 16

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

Haematologica, 2017 Sep 21

British journal of haematology, 2015-12

Blood Adv,

The Lancet. Oncology, 2014-03

The New England journal of medicine, 2012-05-10

Leukemia, 2019-01

Blood, 2017 Aug 3

Blood, 2018 Apr 19

J. Clin. Oncol., 2011 Sep 26

The Lancet. Oncology, 2018-02

Clinical lymphoma, myeloma & leukemia, 2016-09

British journal of haematology, 2016-06

Chest, 1997-03

J. Clin. Oncol.,

Clin Genitourin Cancer, 2017 Sep 04

Eur. Urol., 2020 Jan 01

J. Clin. Oncol., 2019 Sep 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01

International journal of radiation oncology, biology, physics, 2012-11-01

Lancet Oncol., 2008 Jan 15